Important note: Information in this article was accurate in 2002. The state of the art may have changed since the publication date.
PRNewswire - December 10, 2002
These constructs, developed at the National Institute of Allergy and Infectious Disease, National Institutes of Health USA, consist of Modified Vaccinia Ankara (MVA) vectors carrying genes of the Simian Immunodeficiency Virus, or SIV, which, in monkeys, is the equivalent of HIV, which causes AIDS in humans. Transgene will manufacture the lots to be used by IAVI in its pre-clinical studies. Under the agreement, Transgene is entitled to receive payment of an undisclosed amount from IAVI.
"We are pleased to collaborate with such a renowned institution as IAVI on a worldwide public health problem. This agreement is an opportunity for Transgene to leverage its expertise in the production and manufacturing of recombinant vaccines and vectors," said Jean-Francois Carmier, Chief Executive Officer of Transgene.
Transgene, based in Strasbourg, France, with an office near Boston, Massachusetts, is a biopharmaceutical company dedicated to the discovery and development of gene therapy products and delivery technologies for the treatment of diseases for which there is no cure or adequate treatment at present, with a focus on the development of gene therapy products for the treatment of cancer. Transgene has five products in clinical development, two of which are in Phase II clinical trials for seven different indications and three of which are in Phase I clinical trials. Transgene's proprietary vector technology platform consists of multiple vector families with an emphasis on adenovirus, poxvirus and non-viral vectors.
IAVI is a nonprofit organization whose mission is to ensure the development of safe, effective and accessible preventive HIV vaccines for use throughout the world.
This press release contains forward-looking statements. Statements that are not historical facts are based on Transgene's current expectations, beliefs, estimates, forecasts and assumptions. Those statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions which are difficult to predict. Accordingly, actual outcomes and results may differ materially from what is expressed in those forward-looking statements. Important factors that may affect Transgene's future operating results include the following: Transgene's collaboration agreement with IAVI may not provide Transgene with the anticipated benefits when expected, if at all; Transgene's product candidates may not demonstrate therapeutic efficacy; Transgene may be unable to obtain regulatory approval for its product candidates; Transgene's patent rights may not provide it with any benefit and the patents of others may prevent it from commercializing its products; Transgene may be unable to conduct its clinical trials as quickly as it has predicted; Transgene may not have sufficient resources to complete the research and commercialization of any of its product candidates; competitors may develop technologies or products superior to Transgene's technologies or products; and other important factors described in Transgene's Annual Report on Form 20-F for the year ended December 31, 2001 filed with the U.S. Securities and Exchange Commission, including those factors described in the section entitled "Risk Factors."
SOURCE Transgene
021210
PR021220
Copyright © 2002 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .